Related Experiment Video
Updated: Jul 13, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Clinical indications for genetic testing in familial sudden cardiac death syndromes: an HRUK position statement
1Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK. clifford.garratt@cmmc.nhs.uk
Insights
Sudden unexpected death in young individuals may stem from genetic conditions. Genetic testing can now identify at-risk family members, enabling early intervention and prevention of sudden cardiac death.
Area of Science:
- Cardiovascular Genetics
- Clinical Genetics
- Preventative Cardiology
Background:
- Sudden unexpected death in young people carries significant familial implications beyond grief.
- Concerns about inherited genetic conditions and their transmission are common in affected families.
- Advances in genetic testing and preventative treatments are crucial for managing these risks.
Purpose of the Study:
- To provide recommendations for the clinical use of genetic testing in young individuals.
- To outline indications for genetic testing based on inherited cardiac conditions.
- To integrate genetic testing into the prevention of sudden cardiac death.
Main Methods:
- Review of current evidence on inherited cardiac conditions.
- Analysis of the clinical utility of genetic testing techniques.
- Development of guidelines for genetic testing indications.
Main Results:
- Genetic testing can identify individuals at risk for sudden cardiac death before symptom onset.
- Preventative treatments are increasingly available for identified genetic conditions.
- Clinical guidelines are essential for appropriate genetic testing application.
Conclusions:
- Genetic testing offers a vital tool for identifying and managing inherited conditions that cause sudden death in the young.
- Early identification through genetic testing allows for timely preventative strategies.
- Recommendations are provided to guide the clinical implementation of genetic testing for at-risk populations.
Abstract:
The sudden unexpected death of a young person can have profound implications for the surviving family members beyond those associated with bereavement and the immediate sense of loss. Among these other sequelae may be a concern that the sudden death was caused by a genetic condition and that other family members may suffer the same fate. Increased awareness of these inherited conditions and the transfer of the techniques of genetic testing from the research laboratory into the clinical arena make it possible to identify genetically affected individuals before they have symptoms or experience sudden cardiac death. The development of such tests has been paralleled by the emergence of preventative treatments, which have amplified the clinical importance of such tests. This document provides recommendations regarding the clinical indications for these tests based on the best available evidence.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenomics: Identification of New Drug Targets
Cardiomyopathy I: Introduction and Classification
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Acute Coronary Syndrome III: Diagnostic Studies

